| Literature DB >> 28384479 |
Jonathan C Grima1, J Gavin Daigle2, Nicolas Arbez3, Kathleen C Cunningham4, Ke Zhang2, Joseph Ochaba5, Charlene Geater5, Eva Morozko5, Jennifer Stocksdale5, Jenna C Glatzer2, Jacqueline T Pham6, Ishrat Ahmed7, Qi Peng7, Harsh Wadhwa8, Olga Pletnikova9, Juan C Troncoso10, Wenzhen Duan11, Solomon H Snyder3, Laura P W Ranum12, Leslie M Thompson5, Thomas E Lloyd13, Christopher A Ross3, Jeffrey D Rothstein14.
Abstract
Huntington's disease (HD) is caused by an expanded CAG repeat in the Huntingtin (HTT) gene. The mechanism(s) by which mutant HTT (mHTT) causes disease is unclear. Nucleocytoplasmic transport, the trafficking of macromolecules between the nucleus and cytoplasm, is tightly regulated by nuclear pore complexes (NPCs) made up of nucleoporins (NUPs). Previous studies offered clues that mHTT may disrupt nucleocytoplasmic transport and a mutation of an NUP can cause HD-like pathology. Therefore, we evaluated the NPC and nucleocytoplasmic transport in multiple models of HD, including mouse and fly models, neurons transfected with mHTT, HD iPSC-derived neurons, and human HD brain regions. These studies revealed severe mislocalization and aggregation of NUPs and defective nucleocytoplasmic transport. HD repeat-associated non-ATG (RAN) translation proteins also disrupted nucleocytoplasmic transport. Additionally, overexpression of NUPs and treatment with drugs that prevent aberrant NUP biology also mitigated this transport defect and neurotoxicity, providing future novel therapy targets.Entities:
Keywords: C9ORF72; Huntington’s disease; KPT-350; O-GlcNAc; RAN translation; Thiamet-G; induced pluripotent stem cell; neurodegeneration; nuclear pore complex; nucleocytoplasmic transport
Mesh:
Substances:
Year: 2017 PMID: 28384479 PMCID: PMC5595097 DOI: 10.1016/j.neuron.2017.03.023
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173